It said net profit jumped to 12.3 billion euros from 2.8 billion euros in 2019, boosted by a one-time gain of more than 7.0 billion euros from the sale of shares in Regeneron, the US firm leading the pack in antibody treatments for Covid-19.
The board proposed paying a dividend of 3.20 euros a share or more than 4.0 billion euros in all.
The healthy financial performance of the group contrasts with its poor public image in France following a PR debacle surrounding its work developing a vaccine against coronavirus.
In May last year, its British CEO Paul Hudson said the United States would get its jabs before the rest of the world because of Washington's investment in its research, sparking fierce criticism in France.
In the end, the group says it will have its candidate ready only at the end of 2021 and it has announced plans to help rivals Pfizer-BioNTech produce their world-leading innoculation.
>> 'Humiliation': French see Covid-19 vaccine flops as sign of decline
The group's cost-cutting measures, including in its research and development teams in France, have also been criticised in the media and by many French political figures.
In its results statement, the group said it had saved around 1.7 billion euros with cuts last year, around 60 percent of which has been re-invested.
Sanofi, a leading manufacturer of vaccines worldwide, said sales of the products had increased by nearly 9.0 percent to 6.0 billion euros last year, with a 38 percent increase in demand for flu jabs.
(AFP)
ليست هناك تعليقات:
إرسال تعليق